Share-Based Compensation	9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement, Disclosure [Abstract]
Share-Based Compensation	Share-based Compensation In connection with the Separation and the Acquisition, all outstanding restricted stock awards, restricted stock units, and stock options were exchanged for economically equivalent awards of Covetrus. Restricted stock awards and restricted stock units of 327,447 and stock options of 3,914,694 were issued in connection with the exchange. We currently issue shares of restricted stock, restricted stock units, and options to purchase common stock under the Plan. The Plan provides for the grant of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights, other share-based awards, and cash awards. Awards issued under the Plan may not have a term greater than 10 years from the date of grant and generally vest ratably over a three-year period. We utilize the Black-Scholes option pricing model to determine the fair value of options granted and have elected the accrual method for recognizing compensation costs. The fair value of share-based payment awards calculated using the Black-Scholes model varies based on share price, award exercise price, stock volatility, expected term, risk free interest rate, expected dividends, and the assumptions used in determining these variables. During the three and nine months ended September 30, 2019, we granted 166,467 and 1,256,139, respectively, of restricted stock awards and restricted stock units, and 22,540 and 1,003,494, respectively, of stock options with a weighted average fair value of $8.21 and $12.15 per share, respectively, determined using the Black-Scholes option pricing model. For the three and nine months ended September 30, 2019, we recorded share-based compensation expense of $10 million and $35 million, respectively, in connection with share-based payment awards.

Share-based Compensation

In connection with the Separation and the Acquisition, all outstanding restricted stock awards, restricted stock units, and stock options were exchanged for economically equivalent awards of Covetrus. Restricted stock awards and restricted stock units of 327,447 and stock options of 3,914,694 were issued in connection with the exchange.

We currently issue shares of restricted stock, restricted stock units, and options to purchase common stock under the Plan. The Plan provides for the grant of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights, other share-based awards, and cash awards. Awards issued under the Plan may not have a term greater than 10 years from the date of grant and generally vest ratably over a three-year period.

We utilize the Black-Scholes option pricing model to determine the fair value of options granted and have elected the accrual method for recognizing compensation costs. The fair value of share-based payment awards calculated using the Black-Scholes model varies based on share price, award exercise price, stock volatility, expected term, risk free interest rate, expected dividends, and the assumptions used in determining these variables.

During the three and nine months ended September 30, 2019, we granted 166,467 and 1,256,139, respectively, of restricted stock awards and restricted stock units, and 22,540 and 1,003,494, respectively, of stock options with a weighted average fair value of $8.21 and $12.15 per share, respectively, determined using the Black-Scholes option pricing model. For the three and nine months ended September 30, 2019, we recorded share-based compensation expense of $10 million and $35 million, respectively, in connection with share-based payment awards.